Product logins

Find logins to all Clarivate products below.


Unmet Need in Glioblastoma: Can Emerging Immunotherapies Provide the Answer?

Immunotherapy is one of the most exciting areas of oncology drug development. Numerous manufacturers and investors are entering the field and are rapidly expanding and diversifying their portfolios. Given the great unmet need in glioblastoma for therapies able to extend OS, immunotherapy, including novel vaccines and immune checkpoint inhibitors, could provide a valuable treatment option for glioblastoma patients who do not respond to or experience a recurrence of their disease following conventional therapy.

Related Market Assessment Reports

Report
Asthma – Unmet Need – Unmet Need – Severe Asthma (US/EU)
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer…
Report
Hypertension – Unmet Need – Unmet Need – Resistant Hypertension (US/EU)
Resistant hypertension (RHTN) has become a critical focus within the cardiovascular market because a substantial proportion of patients remain uncontrolled despite multidrug therapy, with…
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…
Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…